Shenzhen SiBiono GeneTech Co.,Ltd   Report issue

For profit Phase 2 Phase 4
Founded: Shenzhen China (1998)
Status: Defunct (2021)

Organization Overview

First Clinical Trial
2009
NCT00902122
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 4 Trials (2)

125-iodine (1 trial)

recombinant adenoviral human p53 gene (10 trials)

Drugs in Phase 2 Trials (3)

cisplatin (platinol) (3 trials)

paclitaxel (taxol) (1 trial)

tremelimumab (Imjudo) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Hepatocellular (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 2)

Diabetes Mellitus (Phase 2)

Fallopian Tube Neoplasms (Phase 2)

Head and Neck Neoplasms (Phase 2)

Neoplasms (Phase 4)

Peritoneal Neoplasms (Phase 2)

Pleural Effusion (Phase 2)

Pleural Effusion, Malignant (Phase 2)

Thyroid Diseases (Phase 4)

Thyroid Neoplasms (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 10
  • # of Trial APIs: 5